Today, we shared our financial results for the third quarter of FY2024 and we now expect revenue, Core Operating Profit and Core Operating Profit margin growth this year. Our Growth & Launch Product portfolio, which represents 47% of our total revenue, is delivering strong momentum. Our late-stage pipeline including three Phase 3 programs with planned readouts in calendar year 2025 is advancing. Learn more about our results, outlook, pipeline progress and how we are maximizing our existing portfolio to treat more patients, including information about forward-looking statements and non-IFRS metrics, here: here: https://lnkd.in/gqqx9UBF Sign up for our investor newsletter to stay updated on our milestones and commitments to patients, our people, and the planet: https://lnkd.in/g_qR7cX5
🤝
CEO Japan & Mongolia at JCDecaux - CCEF Japan
2moCongrats Christophe Weber and team